Loading
A phase 2 trial of Glecirasib in pancreatic ductal adenocarcinoma, run by Allist Pharmaceuticals, Inc., now recruiting.
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. is a phase 2 interventional study registered as NCT06008288 by Allist Pharmaceuticals, Inc., with 88 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: JAB-21822.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/